Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014400851> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2014400851 endingPage "38" @default.
- W2014400851 startingPage "27" @default.
- W2014400851 abstract "A cost–utility analysis was conducted to compare the gemcitabine (Gemzar®)/cisplatin and methotrexate/vinblastine(Velban®)/doxorubicin (Doxil®)/cisplatin regimens in the treatment of locally advanced or metastatic bladder cancer. The analysis combined theresults of a cost analysis of a head-to-head Phase III clinical trial with those from a cross-sectional utility study. The analysis was performed from the perspective of the National Health Service in England and Wales. Medical resource use was obtained from the clinical trial database, from which patient-level cost streams were estimated for each treatment group. Unit costs for each resource utilization component were sought from the latest UK cost sources available at the time of analysis (2001). The distribution of the mean total and incremental costs for each group was simulated via bias-adjusted bootstrapping. Time trade-off utilities were derived from the utility study, which aimed to value the superior toxicity profile associated with gemcitabine/cisplatin, given comparable efficacy, in a discrete choice model assessing toxicity attributes and risks. The mean incremental cost of gemcitabine/cisplatin over methotrexate/vinblastine/doxorubicin/cisplatin was estimated to be approximately £2976 per patient, based on a mean of 4.65 cycles per patient treated with gemcitabine/cisplatin compared with a mean of 3.92 cycles per methotrexate/vinblastine/doxorubicin/cisplatin patient. When combined with the utility estimates, this resulted in an incremental cost-effectiveness ratio of approximately £22,925 per quality-adjusted life year gained associated with the choice of gemcitabine/cisplatin over methotrexate/vinblastine/doxorubicin/cisplatin. A 95% confidence interval for the incremental cost-effectiveness ratio was calculated to range from £12,911 to 33,589 per quality-adjusted life year gained. The incremental cost of gemcitabine/cisplatin is primarily due to the direct costs of chemotherapy given minimal cost offsets. However, an incremental cost per quality-adjusted life year ratio in the range of £20,000–30,000 per quality-adjusted life year gained suggested that the regimen is reasonable value for money in England and Wales." @default.
- W2014400851 created "2016-06-24" @default.
- W2014400851 creator A5007084812 @default.
- W2014400851 creator A5007280131 @default.
- W2014400851 creator A5014448128 @default.
- W2014400851 creator A5020804698 @default.
- W2014400851 creator A5026012121 @default.
- W2014400851 creator A5029091154 @default.
- W2014400851 creator A5035050544 @default.
- W2014400851 date "2004-02-01" @default.
- W2014400851 modified "2023-09-26" @default.
- W2014400851 title "Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer" @default.
- W2014400851 cites W1985609148 @default.
- W2014400851 doi "https://doi.org/10.1586/14737167.4.1.27" @default.
- W2014400851 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19807333" @default.
- W2014400851 hasPublicationYear "2004" @default.
- W2014400851 type Work @default.
- W2014400851 sameAs 2014400851 @default.
- W2014400851 citedByCount "18" @default.
- W2014400851 countsByYear W20144008512013 @default.
- W2014400851 countsByYear W20144008512014 @default.
- W2014400851 countsByYear W20144008512015 @default.
- W2014400851 countsByYear W20144008512016 @default.
- W2014400851 countsByYear W20144008512018 @default.
- W2014400851 countsByYear W20144008512021 @default.
- W2014400851 crossrefType "journal-article" @default.
- W2014400851 hasAuthorship W2014400851A5007084812 @default.
- W2014400851 hasAuthorship W2014400851A5007280131 @default.
- W2014400851 hasAuthorship W2014400851A5014448128 @default.
- W2014400851 hasAuthorship W2014400851A5020804698 @default.
- W2014400851 hasAuthorship W2014400851A5026012121 @default.
- W2014400851 hasAuthorship W2014400851A5029091154 @default.
- W2014400851 hasAuthorship W2014400851A5035050544 @default.
- W2014400851 hasConcept C112930515 @default.
- W2014400851 hasConcept C126322002 @default.
- W2014400851 hasConcept C143998085 @default.
- W2014400851 hasConcept C2776694085 @default.
- W2014400851 hasConcept C2777132456 @default.
- W2014400851 hasConcept C2778239845 @default.
- W2014400851 hasConcept C2780258809 @default.
- W2014400851 hasConcept C3019080777 @default.
- W2014400851 hasConcept C64332521 @default.
- W2014400851 hasConcept C71924100 @default.
- W2014400851 hasConceptScore W2014400851C112930515 @default.
- W2014400851 hasConceptScore W2014400851C126322002 @default.
- W2014400851 hasConceptScore W2014400851C143998085 @default.
- W2014400851 hasConceptScore W2014400851C2776694085 @default.
- W2014400851 hasConceptScore W2014400851C2777132456 @default.
- W2014400851 hasConceptScore W2014400851C2778239845 @default.
- W2014400851 hasConceptScore W2014400851C2780258809 @default.
- W2014400851 hasConceptScore W2014400851C3019080777 @default.
- W2014400851 hasConceptScore W2014400851C64332521 @default.
- W2014400851 hasConceptScore W2014400851C71924100 @default.
- W2014400851 hasIssue "1" @default.
- W2014400851 hasLocation W20144008511 @default.
- W2014400851 hasLocation W20144008512 @default.
- W2014400851 hasOpenAccess W2014400851 @default.
- W2014400851 hasPrimaryLocation W20144008511 @default.
- W2014400851 hasRelatedWork W176784858 @default.
- W2014400851 hasRelatedWork W2002112299 @default.
- W2014400851 hasRelatedWork W2018120163 @default.
- W2014400851 hasRelatedWork W2026791198 @default.
- W2014400851 hasRelatedWork W2027766979 @default.
- W2014400851 hasRelatedWork W2027960392 @default.
- W2014400851 hasRelatedWork W2029465486 @default.
- W2014400851 hasRelatedWork W2100029565 @default.
- W2014400851 hasRelatedWork W2987293068 @default.
- W2014400851 hasRelatedWork W3147962601 @default.
- W2014400851 hasVolume "4" @default.
- W2014400851 isParatext "false" @default.
- W2014400851 isRetracted "false" @default.
- W2014400851 magId "2014400851" @default.
- W2014400851 workType "article" @default.